Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a patient with chronic lymphocytic leukemia

Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy

“…The observed clinical response, along with two previously reported cases in the literature, 6,7 highlights the inhibition of the IL-4-related pathways as an effective strategy for the management of EDHM. Given the lack of immunosuppressive activity, dupilumab may represent a safer option than glucocorticoids and immunosuppressants, in terms of risk of infections and leukaemia progression.…”

Targeted inhibition of IL ‐4/13 with dupilumab is an effective treatment for eosinophilic dermatosis of hematologic malignancy

“…The efficacy of dupilumab, an anti-IL-4Rα monoclonal antibody, demonstrates that IL-4 and/or IL-13 may play a significant role in the pathogenesis of EDHM. 1,2 This has previously been reported by Jin et al and Zhai et al 1,2 Treatment options for EDHM are only variably effective and include treatment for underlying CLL, steroids, dapsone, intravenous immunoglobulin (IVIg), colchicine, narrow band UVB, topical steroids, and oral and topical antihistamines. 7 EDHM can be debilitating, hence a reliable treatment with prolonged efficacy is necessary.…”

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

“…More intriguingly, two cases described successful treatment of EDHM with dupilumab, an anti-IL4 and IL-13 receptor monoclonal antibody approved for use in atopic dermatitis [127]. The efficacy of dupilumab further strengthens the hypothesis that Th2-cell activation is a crucial step toward EDHM pathology and opens the way for a 'targeted' approach to EDHM treatment.…”

“…Finally, we show that IL-4 inhibitors hold major promise as a targeted therapeutic approach in patients with EDHM, with an acceptable safety profile owing to a limited impairment of the immune system [ 127 ]. There is a prevailing sentiment that targeting the cytokine milieu of the tumour microenvironment may increase the efficacy of tumour-directed therapies.…”